BioMarin Pharmaceuticals BMRN Total Cost of Revenue
Total Cost of Revenue at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's total cost of revenue?
- BioMarin Pharmaceuticals (BMRN) reported total cost of revenue of $195M in Q1 2026.
- How has BioMarin Pharmaceuticals's total cost of revenue changed year-over-year?
- BioMarin Pharmaceuticals's total cost of revenue increased by 28.7% year-over-year, from $151.56M to $195M.
- What is the long-term trend for BioMarin Pharmaceuticals's total cost of revenue?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's total cost of revenue has grown at a 11.1% compound annual growth rate (CAGR), from $470.52M to $717.44M.
- What does total cost of revenue mean?
- The direct costs incurred to produce and deliver the products sold to customers.
- How do you interpret total cost of revenue?
- An increase relative to revenue may signal rising manufacturing costs or unfavorable product mix, while a decrease suggests improved operational efficiency.
- How does total cost of revenue compare across companies?
- Varies by company based on manufacturing model (in-house vs. outsourced) and product complexity.